(Partially port page to new style; remove elements absent in HTML5; reorganize.) |
|||
Line 1: | Line 1: | ||
− | {{ | + | {{ETH_Zurich/Head_N_Prefix}} |
− | + | ||
<html> | <html> | ||
− | + | <link rel="stylesheet" type="text/css" href="/Template:ETH_Zurich/safety_css?action=raw&ctype=text/css"> | |
+ | </html> | ||
+ | {{ETH_Zurich/Head_N_Suffix}} | ||
+ | {{ETH_Zurich/Header_N}} | ||
+ | <html> | ||
+ | <main role="main"> | ||
<head> | <head> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
<style> | <style> | ||
− | |||
− | |||
body { | body { | ||
font-family: 'Avenir', 'Open Sans', 'HelveticaNeue', 'Helvetica Neue', Helvetica, Arial, sans-serif!important; | font-family: 'Avenir', 'Open Sans', 'HelveticaNeue', 'Helvetica Neue', Helvetica, Arial, sans-serif!important; | ||
} | } | ||
− | |||
div.title { | div.title { | ||
padding: 100px; | padding: 100px; | ||
} | } | ||
− | |||
div.content { | div.content { | ||
Line 39: | Line 26: | ||
line-height: 130%; | line-height: 130%; | ||
} | } | ||
− | |||
img.AND { | img.AND { | ||
− | + | padding-top: 50px; | |
− | + | padding-bottom: 50px; | |
} | } | ||
Line 55: | Line 41: | ||
padding-right: 80px; | padding-right: 80px; | ||
} | } | ||
− | |||
a.more { | a.more { | ||
Line 64: | Line 49: | ||
font-weight: 900; | font-weight: 900; | ||
} | } | ||
− | |||
− | |||
</style> | </style> | ||
− | |||
</head> | </head> | ||
− | + | <div class="title" style="margin:auto"> | |
− | + | <a href="https://2017.igem.org/Team:ETH_Zurich"> | |
− | + | <img src="https://static.igem.org/mediawiki/2017/c/c3/T--ETH_Zurich--Banner.png" width="900px"/> | |
− | + | </a> | |
− | <div class="title"> | + | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
</div> | </div> | ||
− | + | <div style="margin:auto;"> | |
− | < | + | |
<a href="#start"> | <a href="#start"> | ||
− | + | <img src="https://static.igem.org/mediawiki/2017/1/14/T--ETH_Zurich--Scroll.png" width="70px"> | |
</a> | </a> | ||
− | </ | + | </div> |
− | + | ||
<div class="content"> | <div class="content"> | ||
− | + | <div id="start"> | |
− | + | <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p> | |
+ | <p>We need more specific therapies because current approaches result in many side-effects.</p> | ||
+ | <p>That's why we created CATE: Cancer-Targeting E. coli.</p> | ||
+ | <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" width="500px" align="right"> | ||
+ | </div> | ||
− | + | <div id="second"> | |
− | + | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="400px" align="left"> | |
− | + | <p>CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p> | |
− | + | <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a> | |
− | + | </div> | |
− | + | ||
− | + | ||
− | + | <div id="third"> | |
− | + | <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p> | |
− | + | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND" width="730px"> | |
− | + | <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p> | |
− | + | <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a> | |
− | + | ||
− | + | ||
− | + | ||
</div> | </div> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
</div> | </div> | ||
− | + | </main> | |
− | + | <script> | |
− | </ | + | $(function() { |
+ | $('a[href*=#]').on('click', function(e) { | ||
+ | e.preventDefault(); | ||
+ | $('html, body').animate({ scrollTop: $($(this).attr('href')).offset().top}, 500, 'linear'); | ||
+ | }); | ||
+ | }); | ||
+ | </script> | ||
</html> | </html> | ||
− | + | {{ETH_Zurich/Footer_N}} | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + |
Revision as of 04:10, 15 October 2017
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn moreCATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.
Design